| |
Study site
|
Drug regime
|
No of children
|
Incidence rate per 1000 PYAR
|
PE (95 % CI)
|
|---|
|
Dicko [23]
|
Kambila
|
SP (bimonthly)
|
…
|
2.7a
|
40.1 (17.9–56.4)
|
| | |
Control
|
…
|
4.5a
|
–
|
|
Barger Barger [25]
|
Kollé
|
SP + AS
|
91
|
488
|
67 (42–98)
|
| | |
AQ + AS
|
97
|
782
|
47 (32–67)
|
| | |
Placebo
|
96
|
1463
|
–
|
|
Nankabirwa [27]
|
Tororo
|
DP (monthly)
|
236
|
0.01
|
97 (87–98)
|
| | |
DP (three and five monthly)
|
234
|
0.34
|
0.00
|
| | |
Placebo
|
243
|
0.34
|
–
|
-
PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, DP dihydroartemisinin-piperaquine, … data not available, PYAR person-year at risk
-
a5–10 years sub-group
